Part,  Chapter, Paragraph

 1   II,     5.  5.  3|       schizophrenia. Medications (antipsychotics) improve symptoms, while
 2   II,     5.  5.  3|        and relapse prevention are antipsychotics. In general there are little
 3   II,     5.  5.  3|        the spectrum of the use of antipsychotics (not limited to schizophrenia)
 4   II,     5.  5.  3| substantiate that only 30% of the antipsychotics were prescribed to treat
 5   II,     5.  5.  3|          of the second generation antipsychotics have to be re-examined in
 6   II,     5.  5.  3|           research has shown that antipsychotics effectively prevent relapses.
 7   II,     5.  5.  3|   Although some second generation antipsychotics are associated with metabolic
 8   II,     5.  5.  3|           with schizophrenia need antipsychotics not only during the acute
 9   II,     5.  5.  3|           or EUFEST.~Prescription antipsychotics vary widely in European
10   II,     5.  5.  3|         figures, the DDD sales of antipsychotics in Finland is 50% higher
11   II,     5.  5.  3|          prescription of atypical antipsychotics Finland is in the lead,
12   II,     5.  5.  3|          in the UK mostly typical antipsychotics are prescribed, and little
13   II,     5.  5.  3|   extremely unusual high usage of antipsychotics and are probably related
14   II,     5.  5.  3|        probably related to use of antipsychotics for other indications than
15   II,     5.  5.  3|           has a very low usage of antipsychotics compared to other EU countries.~
16   II,     5.  5.  3|          the second generation of antipsychotics – “atypical neuroleptics” –
17   II,     5.  5.  3|           2004, second generation antipsychotics account for 50% in Great
18   II,     5.  5.  3|          5.3.2.5: Prescription of antipsychotics in the year 2002.~The gap
19   II,     5.  5.  3|          patients receiving depot antipsychotics. Br J Psychiatry 153:214-